1. Field of the Invention
This invention pertains to electrodes for nerves and therapeutic signals to be applied to such electrodes. More particularly, this invention pertains to such electrodes and signals for placement on the vagus nerve for treatment of obesity.
2. Prior Art
a. Neural Conduction Block
The Assignee of the present application has a number of pending U.S. patent applications pertaining to application of a conduction block technology to a nerve for a treatment of a variety of disorders. These applications include the following (all filed Sep. 29, 2003): U.S. patent application Ser. No. 10/674,330, which issued as U.S. Pat. No. 7,489,969 (published Sep. 2, 2004 as Publication No. US 2004/0172086 A1); U.S. patent application Ser. No. 10/675,818 (published Sep. 9, 2004 as US Patent Application Publication No. US 2004/0176812 A1), now abandoned, and U.S. patent application Ser. No. 10/674,324 (published Sep. 2, 2004 as US Patent Application Publication No. 2004/0172085 A1), now abandoned. These patent applications describe, in a preferred embodiment, the application of neural conduction block therapy to a vagus nerve alone or in combination with a stimulation of the nerve.
The conduction block therapy includes application of an electrical signal with parameters selected to down-regulate vagal activity by creating conditions in which normal nerve propagation potentials are blocked at the application of the signal on both afferent and efferent nerves fibers of the vagus. A number of different disorders are identified for treatment through the technique. These disorders include obesity, pancreatitis and other gastrointestinal disorders such as irritable bowel syndrome and functional disorders.
Electrodes may be placed directly on the vagus (for example as cuff electrodes) or may be placed on bands surrounding the vagus at the esophagus or placed on an intraluminal device within the esophagus for transmitting the energy from the device across the tissue of the esophagus to the vagus nerves in the region of the esophagus. These embodiments are disclosed with greater particularity in the Assignee's U.S. patent application Ser. No. 10/752,944, which has issued as U.S. Pat. No. 7,167,750, and Ser. No. 10/752,940, which issued as U.S. Pat. No. 7,444,183, both filed Jan. 6, 2004 with respective publication dates of Aug. 26, 2004 and Sep. 2, 2004, Publication Nos. US 2004/0167583 A1 and 2004/0172088 A1.
b. Blocking Signal Parameters and Duty Cycle
On Jun. 30, 2004 the Assignee of the present application filed Ser. No. 10/881,045 (published Feb. 17, 2005 as Publication No. US 2005/0038484 Al), which issued as U.S. Pat. No. 7,844,338, noting that a duty cycle of electrical impulses to the nerve to block neural conduction on the nerve can be adjusted between periods of blocking and no blocking in order to vary the amount of down regulation of the vagus nerve as well as preventing accommodation by the enteric nervous system.
On Jan. 21, 2005 the Assignee filed Ser. No. 11/040,767, which issued as U.S. Pat. No. 7,613,515, describing with greater particularity parameters for controlling block and to avoid accommodation. That application notes that a representative blocking signal is preferably greater than 500 Hz and that such conduction block is preferably within the parameters disclosed in Solomonow, et al. “control of muscle contractile force through indirect high-frequency stimulation”, American Journal of Physical Medicine, Volume 62, No. 2, pages 71-82 (1983). Particularly, the nerve conduction block is applied with electrical signals selected to block the entire cross-section of the nerve (for example, both afferent, efferent, myelinated and non-myelinated fibers) at the site of applying the blocking signal (as opposed to selected sub-groups of nerve fibers or just afferent and not efferent or vice versa).
Preferably, the frequency of the blocking signal is selected to exceed a 200 Hz threshold frequency described in Solomonow, et al. More preferred parameters are a frequency in excess of 500 Hz (with other parameters as non-limiting examples, being an amplitude of 1-8 mA, pulse width of 100 microseconds, and a duty cycle of 5 minutes on and 5 minutes off. A more preferred blocking signal has a frequency of 3,000 Hz to 5,000 Hz or greater applied by either by bi-polar or mono-polar electrodes. Such a signal has a preferred pulse width of 100 micro-seconds (associated with a frequency of 5,000 Hz).
It is believed this frequency and pulse width best avoid neural recovery from blocking and avoid re-polarization of a nerve. A “short-off” time in the pulse cycle (for example, between cycles or within a cycle) can be acceptable as long as it is short enough to avoid nerve re-polarization. The waveform may be a square, triangular or sinusoidal waveform or other shape. The higher frequencies of 5,000 Hz or more have been found, in porcine studies, to result in more consistent neural conduction block. Kilgore, et al., “Nerve Conduction Block Utilizing High-Frequency Alternating Current”, Medical and Biological Engineering and Computing, Vol. 24, pp. 394-406 (2004). Applicants have determined that a signal amplitude of 0.5 mA to 8 mA is adequate for blocking. However, other amplitudes may suffice.
While a duty cycle can be a predetermined time period, it is currently preferred that the duty cycle be less fixed to reduce the likelihood of patient accommodation whereby the autonomic (parasympathetic, sympathetic and enteric) and/or the central nervous systems accommodates for the loss of signals on the vagus or other nerve. While the periods of off and on can be stable or random, they can be set at any fixed or non-fixed sequence (for example, 5 minutes on followed by 5 minutes off repeated for the duration of the therapy or, alternatively, 5 minutes on followed by 10 minutes off as a first cycle with a following cycle meaning a different set of time—such as 10 minutes on and 2 minutes off, with a non-repeating duty cycle continuing over a 24 hour period). Other signal attributes can be varied to reduce the likelihood of accommodation by the nerve or an organ. These include altering the power, waveform or pulse width.
According to a preferred embodiment of the present invention, an apparatus is disclosed for applying a signal to a nerve for the treatment of a disorder. The apparatus includes a first electrode and a second electrode. Each of the electrodes is adapted to be secured to a nerve of a patient. A signal generator is electrically connected to each of the first and second electrodes. The signal generator is adapted to create a signal having a first waveform at the first electrode and a second waveform at the second electrode. The waveforms have parameters selected to block propagation of neural action potentials. The waveforms have a repeating pattern of cycles of pulses with a delay period between at least selected ones of said pulses. In one embodiment, the first and second waveforms are out of phase for a cycle of one of the waveforms to occur during a delay period of the other of the waveforms.
With reference now to the various drawing figures in which identical elements are numbered identically throughout, a description of the preferred embodiment of the present invention will now be provided. The present invention will be described with reference to placing electrodes contacts on both the anterior and posterior vagus nerves overlying the esophagus between a diaphragm and a stomach of a patient for the treatment of obesity. It will be appreciated this is a currently preferred embodiment and the present invention has wider applications as will be apparent to those skilled in the art and can be applied to other cranial nerves (such as the vagus) or peripheral nerves.
Further, while the preferred embodiment illustrates application of a signal to block the propagation of action potentials along a nerve, the present invention is applicable to signals to stimulate a nerve, inhibit nerve function or only partially block a nerve.
1. Alternative Electrode Configurations
In
In each of
Other techniques are known for applying signals directly to a nerve. These include patches placed over the nerve with electrodes on the patch positioned to overly the nerves. In so-called cuff electrodes, a portion of a nerve is dissected to permit a cuff to completely or partially encircle the nerve. An additional optional electrode format is such as that shown in a product brochure called “ATROSTIM Phrenic Nerve Stimulator”, AtroTech Oy, P.O. Box 28, Fin-33721, Tampere, Finland (June 2004). The ATROSTIM nerve stimulator includes electrodes on opposite sides of PTFE strips for placement on opposite sides of a phrenic nerve for quad-polar stimulation. Another phrenic nerve electrode is sold by Avery Laboratories, Inc., 61 Mall Drive, Commack, N.Y., USA. The use of the Avery electrode is described in the website of Avery Laboratories, Inc. at breathingpacemakers.com.
The electrodes E1, E2 are connected by conductors to a pulse generator PG. The pulse generator PG may be a fully implanted unit containing a power source such as batteries or rechargeable batteries, or the like as well as processing controllers for maintaining a desired wave form and duty cycle on the electrodes E1, E2. Also, and as described in the Assignee's earlier described applications, the electrodes E1, E2 can be connected to an implanted antenna for receiving transdermal signals from an external controller transmitted across the patient's skin to the electrode through radio frequency signals. In this later embodiment, the pulse generator PG includes both implanted and external components.
With the arrangement of
In a preferred embodiment for treating obesity, the electrode configuration is that of
2. Nerve-to-Nerve Waveform
a. Continuous Waveform Without Delays Between Pulses
In a preferred embodiment, the amplitude A is preferably between 0.5 mA and 8 mA and more preferably about 4-6 mA. The duration D is, in a preferred embodiment, about 100 microseconds for the total cycle time C (i.e., the time between the initial application of the cycle at t1 and the end of the cycle t3) resulting in a frequency for the cycle of 5,000 Hz. A 100-microsecond pulse duration D for a 5,000 Hz signal results in no time between pulses where there is no signal. Longer pulse durations can be associated with lower frequencies. For example, a 200-microsecond pulse duration and a 2500 Hz frequency signal are also effective blocking signals. Still lower frequency signals are possible for effective blocking. However, it is believed a maximum pulse duration of 1 millisecond with an associated frequency of 500 Hz represents an effective maximum pulse duration to avoid nerve recovery in most patients. A 200 Hz signal as suggested by Solomonow, et al., may still effect a blocking of a nerve.
The cycles of
b. Continuous Waveform With Delays Between Pulses
3. Nerve to Anodic Electrodes Waveforms
Both waveforms W3, W4 are structurally identical having common amplitude A and pulse duration D with the same parameters, in a preferred embodiment, as described with reference to
It will be noted that the two waveforms W3, W4 are out of phase such that the pulse cycle C of one waveform is timed to be occurring during the delay period DP of the other waveform. Further, the delay period DP of a waveform is selected to equal the cycle time C of the other waveform (i.e., twice the pulse duration D). This length of delay period DP is the smallest preferred delay period DP since it results in avoiding an instance where both electrodes E1, E2 are energized which could result in a direct-current component between the electrodes E1, E2. A longer delay period DP could be applied when the delay period length is selected so that the two waveforms continue to avoid having periods of time where both electrodes E1, E2 are receiving a signal simultaneously. The maximum duration of the delay period DP is selected to be less than an amount of time which would otherwise permit the nerve to recover from the blocking signal.
The application of anode A1, A2 is similar to a so-called VDD lead used in cardiac pacing. An example of a VDD electrode is the Solox™ single-lead VDD electrode of Biotronik GmbH & Co., Woermannkehre 1, D-12359 Berlin, Germany. More information is provided at its website biotronik.com. The pacing tip of such electrode in placed in the right ventricle of a heart at the apex and the anode ring resides in the right ventricle.
4. Waveforms with Duty Cycles
In rat studies performed for the assignee, applicants applied blocking signals as described to isolated sciatic nerves of rats. After an effective block was applied and turned off, the nerve recovered in about 10 minutes. In this context, recovery means the nerve response to a stimulus was substantially the same as a baseline response before application of the blocking signal. After about 2.5 minutes, the nerve had recovered about 50% of baseline. Also, the duty cycle can be turned completely off for extended period of times. For example, duty cycle could be applied for a 12-hour period associated with daytime and be continually off with a 12-hour period associated with the evening or during sleep hours.
In
Followed by the pulse duration D1, a period D2 of no treatment for “off” portion of a duty cycle is shown which may last for 5 to 10 minutes associated with an estimate for an amount of time for the nerve to recover. After the off period, a sequence can repeat in identical format. The times of the pulse signal and the off signal may be varied to avoid nerve accommodation. Also, as previously stated, the duty cycle may include extended periods of off-time associated with sleeping or other periods during the day. The “off” period of 5 to 10 minutes avoids nerve accommodation while avoiding complete nerve recovery thereby maintaining therapy efficacy.
5. Programmable Options
As previously noted, the programmable pulse generator PG of
6. Selection of Waveform Parameters
Effective blocking of neural impulses requires treating the nerve with a signal to prevent the depolarization of the nerve that is associated with the conduction of nerve signals (nerve action potentials) past the point of application of the blocking signal. As noted in the assignee's earlier applications (referenced above and incorporated by reference), such depolarization can be achieved by a direct current signal. However, such a signal represents a significant burden to a battery. Low frequency alternating current signals (e.g., less than 20 Hz) permit the nerve to recover. As a result, such signals are useful for stimulating therapies where the nerve is used as a highway for directing the stimulation signal to an organ. Where, as in the present application, the desired therapy is to block the nerve and prevent transmission of neural impulses along the nerve, a higher frequency maintains the nerve in a polarized state. As mentioned above with respect to articles of Solomonow et al. and Kilgore, et al. such frequencies are in excess of 200 Hz and up to 5,000 Hz or more.
Effective blockage of a nerve is a function of both the strength of the signal applied to the nerve as well as the duration of such application.
Using, as an example, a 5,000 Hz signal, such a signal will have a pulse duration (D in
Since neural blockage is jointly dependent upon the amount of charge applied to the nerve and the pulse duration of such application, a blocking therapy can be adjusted for a particular patient.
With the above, a patient being treated for 2.5 minutes at 6 mA at 5 kHz (line A) and who is tolerating the treatment (no associated discomfort) can have the programmable controller programmed to be treated at 5 mA at 5 kHz (line B). With the line B treatment, the amount charge applied to the nerve over the five minute “on” period is the same as the amount of charge which the patient tolerated for 2.5 minutes of the line A “on” period.
While only 5 kHz and 2.5 kHz options are illustrated in this application, any of the blocking frequencies over 200 Hz could be used. In the examples that follow, the following terms have the following meaning:
In
After such impedance check, an initial stimulation signal can be applied to the electrodes (step 203). Preferably, the programmable controller is set to electrode configuration No. 1 (defined above). Unlike the blocking therapeutic signal, the stimulation signal is set at a low enough frequency to result in a signal applied to the electrodes to be propagated to remote sensing equipment or, more preferably, to an organ of the patient which can be monitored to observe a response to the signal. For example, the stomach can be visually observed to note contractions in response to an applied stimulation signal. Alternatively, the stomach contractions can be measured electronically by sensors on the anodic electrodes placed on the stomach as described above. A representative stimulation signal has a frequency of about 12 Hz.
The stimulation testing of
The patient response is observed (step 204). If there is an observed response (e.g., a stomach contraction), the responsive values for the parameters are recorded (step 205). If predetermined ranges of values for such parameters remain to be tested (step 206), the parameters are varied (step 207). For example, amplitude can be increased in value by 1 mA increments while holding pulse duration constant or pulse width can be increased in 100 microsecond increments while holding amplitude constant). After a range of values has been tested (e.g., up to a maximum pulse width of 500 microseconds or a maximum amplitude of 6 mA), the patient is sent to post-operative recovery (step 208.
After any suitable period of post-operative recovery (e.g., fourteen days), the programmable controller can be set to a therapeutic signal parameter as illustrated in the decision tree of
Patient acceptance of the signal is noted (step 302). Acceptance may be any factor but may include pain or discomfort after a short-term application of the signal. A short-term discomfort is suggestive of discomfort due to signal flow through the esophagus in the configuration of
If discomfort is noted (step 302), such parameters may be altered in a manner anticipated to improve comfort (step 307). For example, the electrode configuration No. 2 may be selected or amplitude may be reduced. Patient acceptance is noted (step 308) and acceptance influence parameters are further altered until acceptance is noted. Once acceptance is achieved, remaining parameters are compared to ideal and altered (steps 309-311) in a manner as described above with reference to steps 303-305. For example, if the electrode configuration is altered from configuration No. 1 to configuration No. 2 and acceptance is noted, parameters such as amplitude and frequency may be altered as described above.
a. Circuit Schematic
U.S. Pat. No. 6,895,278 (the “'278 patent”) to Gordon issued May 17, 2005 teaches systems for measuring signals on neuromuscular tissue in the stomach. The '278 patent is incorporated herein by reference.
The resistance RF may be large after first placement of the electrode on the nerve with the resistance reducing in size or magnitude as fibrous growth occurs. Resistance RN represents resistance which is a function of the size of the electrode in contact with the nerve. Resistance RL represents the trans-membrane resistance associated with current leakage through the body of the patient. The capacitance C represents a capacitance associated with charge buildup on the surface of the electrode throughout the cycle of the signal application (also known as polarization of the nerve).
Measurement of impedance on the electrode represents conductivity with the nerve since a low impedance suggests an undesired alternative electrical pathway exists in the patient. A very high impedance suggests a broken electrode or other occurrence of non-conductivity.
The circuit of
The amplifier AC amplifies a charge across resistance Rn of electrode E1. If a amplifier AC is placed across the resistance of Rn, a change in the charge provides an indication of movement of potassium and sodium ions across the cell membranes of the nerve. This provides evidence of depolarization of the nerve.
Accordingly, monitoring of the nerve with a amplifier AC would permit recognizing that the particular set of signal parameters supplied for a particular patient are achieving the desired effect of blocking neural impulses on the nerve. In response to the presence or absence of a detected desired effect, the signal parameters can be modified for a particular patient to achieve the desired effect or to minimize power consumption.
As a practical matter, an amplifier AC cannot be placed solely on the Rn but must be placed across the entire electrode as illustrated with reference to the amplifier AC placed on electrode E1 in
b. Capacitance
While the waveforms in
As shown in
The waveform includes a square area component A1′ and a component A2′ between the square component A1′ and bounded by the slope S. The square component A1′ represents the amount of energy that is being applied to the nerve by the electrode. The remainder of the area A2′ represents wasted energy which is consumed during the pulse but which is absorbed at the electrode-tissue interface and, therefore, not contributing energy to the nerve system.
The volume of the wasted energy component A2′ varies with the capacitance of the electrode. A small capacitance is associated with a large electrode surface area illustrated by the solid curve S. A small electrode surface area is associated with a larger capacitance illustrated by the surface area S1. Therefore, as illustrated in
It is desirable to minimize the amount of wasted energy. Such waste unnecessarily consumes battery power. Accordingly, the amount of wasted energy can minimize by maximizing the surface area of the electrode.
The surface CS′ is formed by nano technology placement of nano-particles. Since the nano-particles appear on the surface CS′ as beads having arcuate individual surfaces, the combined surface area is greatly increased over the flat smooth surface area of
The surface area CS could be increased by any technique which roughens the surface CS. However, the spaces between the modules may be filled with fibrosis which presents a resistance between opposing surfaces. Through use of nano-application of nano-beads, very small separation occurs. The small separation is so small the surface appears smooth and presents an atraumatic surface to opposing tissue. The use of nano-technology to increase a surface area of an electrode to alter its capacitance is known for cochlear implants
c. Controlling Therapy in Response to Detected Neural Activity
A first detection electrode DE1 is positioned on the nerve as is a second detection electrode DE2. The first detection electrode DE1 is positioned between the therapy electrode E and the second detection electrode DE2. The detection electrodes DE1 and DE2 are connected to an amplifier placed in close proximity to the electrodes DE1 and DE2. The amplifier has an output connected to the logic of the pulse generator PG.
Neural impulses are illustrated in
In the event it is desirable to block neural impulses traveling along the direction of arrow A2, as neural impulses pass electrode DE2, they pass a signal to the amplifier A. After a very short period of time (representing the time for a neural impulse to travel the distance between electrodes DE2 and DE1), the pulse NE2 passes electrode DE1 generating a further impulse which is amplified by the amplifier A. The output from the amplifier A is again sent to the pulse generator which can compare the signals indicating that a neural impulse NE2 is traveling in the direction of arrow A2. Recognizing such neural activity in the undesired direction, the pulse generator can then energize the electrode E with a blocking signal selected to block the nerve N and block the neural impulses from passing the electrode E.
The apparatus of
Since neural impulses pass along a nerve at known speeds, preferably, the amplifier A is positioned in very close proximity to the electrodes DE1 and DE2 so that the amplifier A can detect the signals and provide an amplified signal to the pulse generator in time to present an appropriate blocking signal (or stimulation signal) to the therapeutic electrode E.
The polarity of the amplified signal provides a determination of the nerve signal. By applying a polarity discriminator, the direction of the signal can be determined with a single amplifier system and appropriate action of programmable direction blocking can be taken.
With the foregoing detailed description of the present invention, it has been shown how the objects of the invention have been attained in a preferred manner. Modifications and equivalents of disclosed concepts such as those which might readily occur to one skilled in the art, are intended to be included in the scope of the claims which are appended hereto.
This application is a continuation of U.S. patent application No. 11/205,415, filed Aug. 17, 2005, now U.S. Pat. No. 7,672,727, which application is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3128760 | Baker | Apr 1964 | A |
3411507 | Wingrove | Nov 1968 | A |
4114625 | Onat | Sep 1978 | A |
4198963 | Barkalow et al. | Apr 1980 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4702254 | Zabara | Oct 1987 | A |
4776349 | Nashef et al. | Oct 1988 | A |
4867164 | Zabara | Sep 1989 | A |
4979511 | Terry et al. | Dec 1990 | A |
5025807 | Zabara | Jun 1991 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5199430 | Fang et al. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215089 | Baker, Jr. et al. | Jun 1993 | A |
5226429 | Kuzmak | Jul 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5292344 | Douglas | Mar 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5335657 | Terry et al. | Aug 1994 | A |
5344438 | Testerman | Sep 1994 | A |
5370675 | Edwards et al. | Dec 1994 | A |
5423872 | Cigaina | Jun 1995 | A |
5437291 | Pasricha et al. | Aug 1995 | A |
5514175 | Kim et al. | May 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5601604 | Vincent | Feb 1997 | A |
5620955 | Knight et al. | Apr 1997 | A |
5690691 | Chen et al. | Nov 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5716385 | Mittal et al. | Feb 1998 | A |
5747060 | Sackler et al. | May 1998 | A |
5749907 | Mann | May 1998 | A |
5830434 | Taylor et al. | Nov 1998 | A |
5836994 | Bourgeois | Nov 1998 | A |
5861014 | Familoni | Jan 1999 | A |
5919216 | Houben et al. | Jul 1999 | A |
5967977 | Mullis et al. | Oct 1999 | A |
5995872 | Bourgeois | Nov 1999 | A |
6002964 | Feler et al. | Dec 1999 | A |
6083249 | Familoni | Jul 2000 | A |
6091992 | Bourgeois et al. | Jul 2000 | A |
6093167 | Houben et al. | Jul 2000 | A |
6097984 | Douglas | Aug 2000 | A |
6098629 | Johnson et al. | Aug 2000 | A |
6104955 | Bourgeois | Aug 2000 | A |
6111715 | Tsuchiya et al. | Aug 2000 | A |
6129726 | Edwards | Oct 2000 | A |
6135978 | Houben et al. | Oct 2000 | A |
6148222 | Ramsey, III | Nov 2000 | A |
6216039 | Bourgeois | Apr 2001 | B1 |
6238423 | Bardy | May 2001 | B1 |
6243607 | Mintchev et al. | Jun 2001 | B1 |
6261280 | Houben et al. | Jul 2001 | B1 |
6261572 | Donovan | Jul 2001 | B1 |
6290961 | Aoki et al. | Sep 2001 | B1 |
6292703 | Meier et al. | Sep 2001 | B1 |
6308105 | Duysens et al. | Oct 2001 | B1 |
6312708 | Donovan | Nov 2001 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6364899 | Dobak, III | Apr 2002 | B1 |
6369079 | Rubin et al. | Apr 2002 | B1 |
6405732 | Edwards et al. | Jun 2002 | B1 |
6418346 | Nelson et al. | Jul 2002 | B1 |
6449511 | Mintchev et al. | Sep 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6532388 | Hill et al. | Mar 2003 | B1 |
6558708 | Lin | May 2003 | B1 |
6571127 | Ben-Haim et al. | May 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587725 | Durand et al. | Jul 2003 | B1 |
6591137 | Fischell | Jul 2003 | B1 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6612983 | Marchal | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6746474 | Saadat | Jun 2004 | B2 |
6760626 | Boveja | Jul 2004 | B1 |
6826428 | Chen et al. | Nov 2004 | B1 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6853862 | Marchal et al. | Feb 2005 | B1 |
6879859 | Boveja | Apr 2005 | B1 |
6895278 | Gordon | May 2005 | B1 |
6928320 | King | Aug 2005 | B2 |
6993391 | Flesler et al. | Jan 2006 | B2 |
7054690 | Imran | May 2006 | B2 |
7072720 | Puskas | Jul 2006 | B2 |
7076307 | Boveja et al. | Jul 2006 | B2 |
7142910 | Puskas | Nov 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7292890 | Whitehurst et al. | Nov 2007 | B2 |
7299091 | Barrett et al. | Nov 2007 | B2 |
7340306 | Barrett | Mar 2008 | B2 |
7346398 | Gross et al. | Mar 2008 | B2 |
7389145 | Kilgore et al. | Jun 2008 | B2 |
7444183 | Knudson et al. | Oct 2008 | B2 |
7444184 | Boveja | Oct 2008 | B2 |
7489969 | Knudson et al. | Feb 2009 | B2 |
7613515 | Knudson et al. | Nov 2009 | B2 |
7620454 | Dinsmoor et al. | Nov 2009 | B2 |
7620455 | Maschino | Nov 2009 | B2 |
7630769 | Knudson | Dec 2009 | B2 |
7672727 | Donders et al. | Mar 2010 | B2 |
7693577 | Knudson | Apr 2010 | B2 |
7720540 | Knudson et al. | May 2010 | B2 |
7729771 | Knudson | Jun 2010 | B2 |
7822486 | Foster et al. | Oct 2010 | B2 |
7844338 | Knudson et al. | Nov 2010 | B2 |
7917226 | Nghiem et al. | Mar 2011 | B2 |
7986995 | Knudson et al. | Jul 2011 | B2 |
20010012828 | Aoki et al. | Aug 2001 | A1 |
20010051787 | Haller et al. | Dec 2001 | A1 |
20020016617 | Oldham | Feb 2002 | A1 |
20020032468 | Hill et al. | Mar 2002 | A1 |
20020052336 | Yerxa et al. | May 2002 | A1 |
20020055779 | Andrews | May 2002 | A1 |
20020072780 | Foley | Jun 2002 | A1 |
20020087192 | Barrett et al. | Jul 2002 | A1 |
20020094962 | Ashley et al. | Jul 2002 | A1 |
20020103424 | Swoyer et al. | Aug 2002 | A1 |
20020161360 | Carroll | Oct 2002 | A1 |
20020198570 | Puskas | Dec 2002 | A1 |
20020198571 | Puskas | Dec 2002 | A1 |
20030014086 | Sharma | Jan 2003 | A1 |
20030018367 | DiLorenzo | Jan 2003 | A1 |
20030040785 | Maschino et al. | Feb 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030045914 | Cohen et al. | Mar 2003 | A1 |
20030074039 | Puskas | Apr 2003 | A1 |
20030135245 | Campos | Jul 2003 | A1 |
20030135248 | Stypulkowski | Jul 2003 | A1 |
20030144709 | Zabara et al. | Jul 2003 | A1 |
20030171789 | Malek et al. | Sep 2003 | A1 |
20030181958 | Dobak, III | Sep 2003 | A1 |
20030181959 | Dobak, III | Sep 2003 | A1 |
20030195601 | Hung et al. | Oct 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20040039425 | Greenwood-Van Meerveld | Feb 2004 | A1 |
20040039427 | Barrett et al. | Feb 2004 | A1 |
20040059383 | Puskas | Mar 2004 | A1 |
20040086531 | Barron | May 2004 | A1 |
20040089313 | Utley et al. | May 2004 | A1 |
20040111126 | Tanagho et al. | Jun 2004 | A1 |
20040127953 | Kilgore et al. | Jul 2004 | A1 |
20040167583 | Knudson et al. | Aug 2004 | A1 |
20040172084 | Knudson et al. | Sep 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172086 | Knudson et al. | Sep 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040181178 | Aldrich et al. | Sep 2004 | A1 |
20040193229 | Starkebaum et al. | Sep 2004 | A1 |
20040236381 | Dinsmoor et al. | Nov 2004 | A1 |
20040236382 | Dinsmoor et al. | Nov 2004 | A1 |
20040243182 | Cohen et al. | Dec 2004 | A1 |
20040249416 | Yun et al. | Dec 2004 | A1 |
20040254616 | Rossing et al. | Dec 2004 | A1 |
20050038484 | Knudson et al. | Feb 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050070970 | Knudson et al. | Mar 2005 | A1 |
20050070974 | Knudson et al. | Mar 2005 | A1 |
20050075693 | Toy et al. | Apr 2005 | A1 |
20050131485 | Knudson et al. | Jun 2005 | A1 |
20050137644 | Boveja et al. | Jun 2005 | A1 |
20050143378 | Yun et al. | Jun 2005 | A1 |
20050143412 | Puskas | Jun 2005 | A1 |
20050143787 | Boveja et al. | Jun 2005 | A1 |
20050149141 | Starkebaum | Jul 2005 | A1 |
20050149146 | Boveja et al. | Jul 2005 | A1 |
20050149148 | King | Jul 2005 | A1 |
20050203501 | Aldrich et al. | Sep 2005 | A1 |
20050240231 | Aldrich et al. | Oct 2005 | A1 |
20050267542 | David et al. | Dec 2005 | A1 |
20060015151 | Aldrich | Jan 2006 | A1 |
20060030919 | Mrva et al. | Feb 2006 | A1 |
20060036293 | Whitehurst et al. | Feb 2006 | A1 |
20060041277 | Deem | Feb 2006 | A1 |
20060100668 | Ben-david et al. | May 2006 | A1 |
20060190053 | Dobak, III | Aug 2006 | A1 |
20060212089 | Tass et al. | Sep 2006 | A1 |
20060229685 | Knudson et al. | Oct 2006 | A1 |
20060247737 | Olson | Nov 2006 | A1 |
20070027484 | Guzman et al. | Feb 2007 | A1 |
20070043400 | Donders et al. | Feb 2007 | A1 |
20070100377 | Armstrong et al. | May 2007 | A1 |
20070135846 | Knudson et al. | Jun 2007 | A1 |
20070135856 | Knudson et al. | Jun 2007 | A1 |
20070135857 | Knudson et al. | Jun 2007 | A1 |
20070135858 | Knudson et al. | Jun 2007 | A1 |
20070142870 | Knudson et al. | Jun 2007 | A1 |
20070203521 | Dobak et al. | Aug 2007 | A1 |
20080021512 | Knudson et al. | Jan 2008 | A1 |
20080300654 | Lambert et al. | Dec 2008 | A1 |
20090306739 | Dilorenzo | Dec 2009 | A1 |
Number | Date | Country |
---|---|---|
1 666 087 | Feb 1998 | EP |
0 865 800 | Sep 1998 | EP |
0 896 828 | Feb 1999 | EP |
1 004 330 | May 2000 | EP |
WO 0141671 | Jun 2001 | WO |
WO 0143821 | Jun 2001 | WO |
WO 0226320 | Apr 2002 | WO |
WO 02065896 | Aug 2002 | WO |
WO 2004036377 | Apr 2004 | WO |
WO 2004064918 | Aug 2004 | WO |
WO 2004082763 | Sep 2004 | WO |
WO 2004093981 | Nov 2004 | WO |
WO 2004110551 | Dec 2004 | WO |
WO 2006023498 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20100094375 A1 | Apr 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11205415 | Aug 2005 | US |
Child | 12638266 | US |